Keck School Faculty

Belimumab for the treatment of pediatric patients with lupus nephritis Expert Opin Biol Ther. 2023 03; 23(3):243-251. . View in PubMed

Maternal and cord blood BAFF and APRIL levels during pregnancy Am J Reprod Immunol. 2023 03; 89(3):e13654. . View in PubMed

Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms Commun Biol. 2023 03 20; 6(1):295. . View in PubMed

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828. . View in PubMed

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE Lupus Sci Med. 2022 02; 9(1). . View in PubMed

Preferential Expansion of Foxp3+ T Regulatory Cells in CTLA-4-Deficient and CTLA-4-Haploinsufficient C57BL/6 Mice Immunohorizons. 2022 07 25; 6(7):507-514. . View in PubMed

B Cell and T Cell Dissimilarities in BAFF-Deficient versus BR3-Deficient C57BL/6 Mice J Immunol. 2022 12 01; 209(11):2133-2140. . View in PubMed

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-a/-? inhibition. Lupus. 2021 Apr; 30(5):795-806.. View in PubMed

First-trimester serum BAFF:sFlt-1 ratio as a candidate early biomarker of spontaneous abortion Am J Reprod Immunol. 2021 10; 86(4):e13428. . View in PubMed

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial Ann Rheum Dis. 2021 06; 80(6):727-738. . View in PubMed

J Transl Autoimmun. 2021; 4:100075. . View in PubMed

Systemic lupus erythematosus (SLE): emerging therapeutic targets Expert Opin Ther Targets. 2020 12; 24(12):1283-1302. . View in PubMed

Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF Arthritis Rheumatol. 2020 02; 72(2):292-302. . View in PubMed

Promotion of T Regulatory Cells in Mice by B Cells and BAFF J Immunol. 2020 05 01; 204(9):2416-2428. . View in PubMed

Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF Arthritis Res Ther. 2020 05 07; 22(1):106. . View in PubMed

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents Front Med (Lausanne). 2020; 7:303. . View in PubMed

The safety of belimumab for the treatment of systemic lupus erythematosus Expert Opin Drug Saf. 2019 Dec; 18(12):1133-1144. . View in PubMed

Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases Semin Arthritis Rheum. 2019 12; 49(3):485-492. . View in PubMed

IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation J Invest Dermatol. 2019 12; 139(12):2477-2487. . View in PubMed

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus Arthritis Rheumatol. 2019 07; 71(7):1125-1134. . View in PubMed

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice Lupus Sci Med. 2019; 6(1):e000313. . View in PubMed

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus Lupus. 2018 Aug; 27(9):1489-1498. . View in PubMed

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus Arthritis Rheumatol. 2018 08; 70(8):1256-1264. . View in PubMed

Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients Sci Rep. 2018 07 23; 8(1):11044. . View in PubMed

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study Lupus Sci Med. 2018; 5(1):e000288. . View in PubMed

A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens J Clin Invest. 2017 May 01; 127(5):1651-1663. . View in PubMed

Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study Clin Rheumatol. 2017 Mar; 36(3):507-516. . View in PubMed

Maternal Serum B-Cell Activating Factor Levels: Candidate Early Biomarker for Hypertensive Disorders of Pregnancy Hypertension. 2017 11; 70(5):1007-1013. . View in PubMed

Systemic lupus erythematosus: BAFF emerges from the genetic shadows Nat Rev Rheumatol. 2017 08; 13(8):456-457. . View in PubMed

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE) Expert Rev Clin Immunol. 2017 06; 13(6):623-633. . View in PubMed

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study Arthritis Rheumatol. 2017 05; 69(5):1016-1027. . View in PubMed

B cell-independent contribution of BAFF to murine autoimmune disease Clin Immunol. 2016 Nov; 172:111-116. . View in PubMed

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study Ann Rheum Dis. 2016 Feb; 75(2):332-40. . View in PubMed

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors Arthritis Rheumatol. 2015 Sep; 67(9):2523-35. . View in PubMed

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials Arthritis Res Ther. 2015 Aug 20; 17:215. . View in PubMed

A dendritic-cell-stromal axis maintains immune responses in lymph nodes Immunity. 2015 Apr 21; 42(4):719-30. . View in PubMed

Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells Arthritis Rheumatol. 2015 Mar; 67(3):612-5. . View in PubMed

APRIL mediates peritoneal B-1 cell homeostasis Immunol Lett. 2014 Aug; 160(2):120-7. . View in PubMed

Tear cathepsin S as a candidate biomarker for Sjögren's syndrome Arthritis Rheumatol. 2014 Jul; 66(7):1872-81. . View in PubMed

Arthritis Rheumatol. 2014 May; 66(5):1153-64. . View in PubMed

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus Expert Opin Ther Targets. 2014 Apr; 18(4):473-89. . View in PubMed

Lloyd Mayer, MD, 1952-2013, In Memoriam Clin Immunol. 2014 Feb; 150(2):A1-A2. . View in PubMed

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus J Rheumatol. 2014 Feb; 41(2):300-9. . View in PubMed

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation J Exp Med. 2014 Jan 13; 211(1):45-56. . View in PubMed

Future prospects in biologic therapy for systemic lupus erythematosus Nat Rev Rheumatol. 2013 Dec; 9(12):705-20. . View in PubMed

BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand J Immunol. 2013 Aug 01; 191(3):1154-63. . View in PubMed

Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data Health Econ. 2013 Jul; 22(7):807-23. . View in PubMed

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study J Rheumatol. 2013 May; 40(5):579-89. . View in PubMed

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor Arthritis Rheum. 2013 Apr; 65(4):1043-54. . View in PubMed

Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. . View in PubMed

Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells Ann Rheum Dis. 2012 Sep; 71(9):1567-1572. . View in PubMed

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9.. View in PubMed

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial J Rheumatol. 2012 Aug; 39(8):1632-40. . View in PubMed

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial Ann Rheum Dis. 2012 Aug; 71(8):1289-96. . View in PubMed

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus Arthritis Rheum. 2012 Jul; 64(7):2328-37. . View in PubMed

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice Arthritis Rheum. 2012 May; 64(5):1610-9. . View in PubMed

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE Ann Rheum Dis. 2012 Mar; 71(3):351-7. . View in PubMed

The discovery and development of belimumab: the anti-BLyS-lupus connection Nat Biotechnol. 2012 Jan 09; 30(1):69-77. . View in PubMed

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Rheum. 2011 Dec; 63(12):3918-30. . View in PubMed

Cytokine disturbances in systemic lupus erythematosus Arthritis Res Ther. 2011 Jul 06; 13(4):228. . View in PubMed

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside Curr Opin Rheumatol. 2011 May; 23(3):305-10. . View in PubMed

B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice J Immunol. 2011 Apr 15; 186(8):4984-93. . View in PubMed

J Immunol. 2011 Apr 01; 186(7):4223-33. . View in PubMed

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Ann Rheum Dis. 2011 Jan; 70(1):39-46. . View in PubMed

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis PLoS One. 2011; 6(8):e23629. . View in PubMed

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity Arthritis Rheum. 2010 Aug; 62(8):2432-42. . View in PubMed

Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future Autoimmunity. 2010 Feb; 43(1):84-97. . View in PubMed

Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Arthritis Rheum. 2010 Feb; 62(2):392-401. . View in PubMed

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes) Arthritis Res Ther. 2010; 12(2):111. . View in PubMed

Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis Ann Rheum Dis. 2009 Nov; 68(11):1768-74. . View in PubMed

Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease J Immunol. 2009 Nov 01; 183(9):6021-9. . View in PubMed

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients Arthritis Rheum. 2009 Nov; 60(11):3400-9. . View in PubMed

Novel evidence-based systemic lupus erythematosus responder index Arthritis Rheum. 2009 Sep 15; 61(9):1143-51. . View in PubMed

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. . View in PubMed

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway J Immunol. 2009 Feb 15; 182(4):2532-41. . View in PubMed

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study Arthritis Res Ther. 2009; 11(5):R143. . View in PubMed

B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders Ann Rheum Dis. 2008 Aug; 67(8):1132-8. . View in PubMed

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus Arthritis Rheum. 2008 Aug; 58(8):2453-9. . View in PubMed

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response Ann Rheum Dis. 2008 Jul; 67(7):1011-6. . View in PubMed

Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity J Immunol. 2008 Jul 01; 181(1):833-41. . View in PubMed

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Arthritis Res Ther. 2008; 10(5):R109. . View in PubMed

New and promising treatments for rheumatoid arthritis Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23. . View in PubMed

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8. . View in PubMed

Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI) Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45. . View in PubMed

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12.. View in PubMed

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF J Immunol. 2006 Aug 15; 177(4):2671-80. . View in PubMed

TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells J Immunol. 2006 Mar 15; 176(6):3321-9. . View in PubMed

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse Arthritis Rheum. 2006 Mar; 54(3):723-32. . View in PubMed

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels Arthritis Res Ther. 2006; 8(1):R6. . View in PubMed

Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II Clin Immunol. 2005 Sep; 116(3):257-64. . View in PubMed

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus Arthritis Rheum. 2005 Jul; 52(7):2080-91. . View in PubMed

Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis Ann Rheum Dis. 2005 May; 64(5):743-9. . View in PubMed

BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists Curr Dir Autoimmun. 2005; 8:289-304. . View in PubMed

Increased CXCL8 (IL-8) expression in Multiple Sclerosis J Neuroimmunol. 2004 Oct; 155(1-2):161-71. . View in PubMed

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus Ann Rheum Dis. 2004 Sep; 63(9):1096-103. . View in PubMed

Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice Arthritis Rheum. 2004 Jul; 50(7):2227-39. . View in PubMed

MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4) Int Immunol. 2004 Jul; 16(7):895-904. . View in PubMed

Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders Expert Opin Ther Targets. 2004 Jun; 8(3):177-89. . View in PubMed

A therapeutic role for BLyS antagonists Lupus. 2004; 13(5):317-22. . View in PubMed

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations Arthritis Rheum. 2003 Dec; 48(12):3475-86. . View in PubMed

In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens Clin Immunol. 2003 Sep; 108(3):182-9. . View in PubMed

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis Arthritis Rheum. 2003 Apr; 48(4):982-92. . View in PubMed

SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder Arthritis Res Ther. 2003; 5(3):136-8. . View in PubMed

B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases Curr Rheumatol Rep. 2002 Aug; 4(4):345-50. . View in PubMed

B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients Clin Immunol. 2002 Aug; 104(2):115-22. . View in PubMed

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum. 2001 Jun; 44(6):1313-9. . View in PubMed

Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death Cell Immunol. 2000 Jul 10; 203(1):1-11. . View in PubMed

Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells Lupus. 1999; 8(4):293-9. . View in PubMed

Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells J Immunol. 1998 Oct 01; 161(7):3292-8. . View in PubMed

CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses J Immunol. 1998 Jun 01; 160(11):5231-8. . View in PubMed

TCR AV24 gene expression in double negative T cells in systemic lupus erythematosus Lupus. 1998; 7(8):565-8. . View in PubMed

Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin Arthritis Rheum. 1997 Jun; 40(6):1130-7. . View in PubMed

Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulationStudies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum. 1996 Nov; 39(11):1840-51. . View in PubMed

Treatment of rheumatoid arthritis N Engl J Med. 1996 Sep 12; 335(11):821-2; author reply 822-3. . View in PubMed

In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens Clin Immunol Immunopathol. 1996 May; 79(2):122-33. . View in PubMed

Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg)Regulatory role for SAg-dependent B cell cytolysis. J Immunol. 1995 Aug 15; 155(4):1838-50. . View in PubMed

Impaired polyclonal T cell cytolytic activityA possible risk factor for systemic lupus erythematosus. Arthritis Rheum. 1995 Apr; 38(4):506-16. . View in PubMed

Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation Cell Immunol. 1994 Sep; 157(2):381-92. . View in PubMed

Polyclonal in vitro T cell proliferation and T cell-dependent B cell differentiation supported by activated autologous B cells Clin Immunol Immunopathol. 1994 Jul; 72(1):44-52. . View in PubMed

Human T cell-dependent B cell differentiation induced by staphylococcal superantigens J Immunol. 1994 Jul 01; 153(1):117-27. . View in PubMed

Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity Clin Immunol Immunopathol. 1992 Oct; 65(1):30-8. . View in PubMed

Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus Clin Immunol Immunopathol. 1992 May; 63(2):163-72. . View in PubMed

Induction of human T cell proliferation by a monoclonal antibody to CD5 J Immunol. 1991 Jan 01; 146(1):47-52. . View in PubMed

Inhibition by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell-dependent B cell activation Cell Immunol. 1990 Oct 15; 130(2):257-70. . View in PubMed

Differential CD3/T cell antigen receptor-mediated IL-2 production in jurkat T cellsDissociation of IL-2 response from total inositol phosphate and calcium responses. J Immunol. 1990 Aug 15; 145(4):1078-87. . View in PubMed

Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components J Immunol. 1990 May 15; 144(10):3718-25. . View in PubMed

A novel role for accessory cells in T cell-dependent B cell differentiation Cell Immunol. 1990 May; 127(2):458-69. . View in PubMed

A functionally unique anti-CD3 monoclonal antibody cross-reactive with basal keratinocytes Cell Immunol. 1989 Jul; 121(2):247-60. . View in PubMed

Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen Cell Immunol. 1989 Jun; 121(1):99-112. . View in PubMed

Inhibitory effects of anti-CD2 monoclonal antibodies on interleukin 2 production and interleukin 2 receptor expression in anti-CD3-induced T cell activation Cell Immunol. 1989 May; 120(2):351-65. . View in PubMed

Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells J Immunol. 1989 Apr 01; 142(7):2343-51. . View in PubMed

Feedback inhibition of B cell differentiation by monomeric immunoglobulin Int Rev Immunol. 1989; 5(2):189-95. . View in PubMed

In vitro induction of T cell-dependent B cell differentiation in patients with common varied immunodeficiency Clin Immunol Immunopathol. 1988 Nov; 49(2):273-82. . View in PubMed

Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation Cell Immunol. 1988 Oct 01; 116(1):73-85. . View in PubMed

Correlation between systemic lupus erythematosus and T4 epitope phenotype Arthritis Rheum. 1987 Dec; 30(12):1412-5. . View in PubMed

Inhibition of T cell-dependent human B cell proliferation and B cell differentiation by polyspecific monomeric IgG Clin Exp Immunol. 1987 Dec; 70(3):649-57. . View in PubMed

Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies J Immunol. 1987 Mar 15; 138(6):1667-73. . View in PubMed

Modulation of the immune response by immunoglobulin for intravenous useII. Inhibitory effects of sera from treated patients. Clin Immunol Immunopathol. 1986 Nov; 41(2):273-80. . View in PubMed

Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use J Immunol. 1986 Jun 15; 136(12):4407-13. . View in PubMed

Modulation of the immune response by immunoglobulin for intravenous useI. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol. 1985 Oct; 62(1):200-7. . View in PubMed

Systemic lupus erythematosus with deficiency of the T4 epitope on T helper/inducer cells N Engl J Med. 1985 Jun 27; 312(26):1671-8. . View in PubMed

Heterogeneity in expression of the T4 epitope in black individuals Scand J Immunol. 1984 Sep; 20(3):273-8. . View in PubMed

Deficient OKT4 epitope on helper T cells in patient with SLE: confusion with AIDS N Engl J Med. 1984 Jun 07; 310(23):1531. . View in PubMed

Detection of the precursor and effector cells of experimental allergic encephalomyelitis in the thoracic duct of the rat Cell Immunol. 1980 Sep 01; 54(2):471-7. . View in PubMed

Saturday classes and rounds N Engl J Med. 1979 May 17; 300(20):1165. . View in PubMed

A quantitative assay for experimental allergic encephalomyelitis in the rat based on permeability of spinal cords to 125I-human gamma-globulin J Immunol. 1979 Mar; 122(3):920-5. . View in PubMed

Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat J Immunol. 1978 Sep; 121(3):844-50. . View in PubMed

Religious objections to autopsy N Engl J Med. 1977 Oct 27; 297(17):953. . View in PubMed

Distribution of the thy-1 antigen in cellular and subcellular fractions of adult mouse brain J Immunol. 1977 Aug; 119(2):422-7. . View in PubMed